metastatic uveal melanoma
Apr 14, 2026
IDEAYA and Servier Reports Successful Uveal Melanoma Trial; SynOx Therapeutics Highlights Positive Phase 3 TANGENT Topline Data; Regeneron and Telix Ink Strategic Radiopharma Deal; GSK Shares Promising Clinical Data on B7-H4-Targeted ADC; Replimune’s RP1 Hits Regulatory Hurdle with FDA Complete Response Letter
IDEAYA Biosciences and Servier Advance Darovasertib Program with Positive Registrational Trial Results IDEAYA Biosciences and Servier have announced positive topline findings from the Phase 2/3 OptimUM-02 registrational trial evaluating the combination of darovasertib and crizotinib. The study targeted patients ...
Read More...
Jan 01, 2024
The Rise of TCR Therapy: A Beacon of Hope in Cancer Treatment
T-cell receptor (TCR)-dependent treatment involves modified immune cells aimed at attacking particular tumor indicators. This treatment approach necessitates a systematic procedure including patient evaluation (e.g., for HLA-A*02:01 and precise tumor markers), collecting immune cells, creating the altered TCR produ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
